AI Drug Discovery Market Poised to Reach Nearly $3 Billion by 2026 Amid Accelerating Global Collaborations

　　【Pharmaceutical Network Market Analysis] AI drug discovery, based on big pharmaceutical data, applies artificial intelligence technology to various stages of drug development, improving the efficiency and quality of new drug research while reducing costs. In recent years, AI drug discovery has garnered significant attention in the industry. Data shows that the global AI drug discovery market size was $1.04 billion in 2022 and is expected to grow to $2.994 billion by 2026.
 

The AI pharmaceuticals market has broad prospects, which is also driving accelerated cooperation in the global AI pharmaceuticals field. For instance, Isomorphic Labs, an AI medicine company, announced agreements with Eli Lilly and Novartis to form partnerships that will apply AI technology to the discovery of new drugs.
 

It is reported that the collaboration between Isomorphic Labs and Novartis will focus on developing small molecule drugs for three undisclosed targets. Isomorphic Labs will receive an upfront payment of $37.5 million and is eligible for up to $1.2 billion in milestone payments. The collaboration between Isomorphic Labs and Eli Lilly will aim to develop small molecule drugs for multiple targets. Isomorphic Labs will receive an upfront payment of $45 million and is eligible for up to $1.7 billion in milestone payments.
 

Meanwhile, AI drug discovery company Insilico Medicine also announced a licensing collaboration worth over US$500 million with Italian pharmaceutical company Menarini Group and its wholly-owned subsidiary Stemline Therapeutics. Additionally, BOC Sciences stated that the company signed a strategic cooperation agreement with Shenzhen Eiger BioPharmaceuticals Co., Ltd., and will utilize artificial intelligence to carry out strategic cooperation in the clinical trial field in the future. Moreover, CRO enterprises such as Viva Biotech and Chengdu先导 (Chengdu Lead) have frequently collaborated with AI technology companies in recent years, involving target research and clinical trials.
 

Analysts pointed out that, from the perspective of the Chinese market, the AI drug research and development industry started relatively late. The market size in 2023 is expected to be approximately 400 million RMB, but capital is flooding into this market on a large scale. Statistics show that in the first three quarters of 2023, there were over 20 financing events for Chinese AI pharmaceutical companies, with most of these financed enterprises still in the early stages of development.
 

However, other sources pointed out that after reaching the peak of investment and financing in 2022, AI pharmaceutical-related investment and financing activities have started to slow down globally. Data shows that in the past three years (2021-2023 Q3), the total global AI pharmaceutical financing amounted to approximately USD 13.466 billion. Specifically, in 2021 and 2022, this field completed financings of USD 4.295 billion and USD 6.361 billion respectively, with 73 and 144 financing activities respectively. In the first three quarters of 2023, the completed financing amount was USD 2.81 billion, involving 75 financing activities. Compared with the same period in 2022, activity in the first three quarters of 2023 decreased by about 36%.
 

In addition, according to data statistics, in January 2024, five AI pharmaceutical enterprises worldwide completed a new round of financing, representing a decrease in frequency compared to 2022 and 2023.
 

However, some institutions believe that the role of AI technology in reducing costs and improving efficiency in the drug research and development process has been recognized. At the same time, for technology companies with core advantages in algorithms and computing power, their technologies can be validated and transformed into value. In the future, with the arrival of a global wave of innovative drug research and development, the AI pharmaceuticals industry is increasingly favored by the capital market.
 

In the Chinese market, the support for AI pharmaceuticals from policies is also increasing. As pointed out in the "14th Five-Year Plan for the Pharmaceutical Industry," exploring the application of artificial intelligence, cloud computing, big data, and other technologies in research and development fields, by mining and analyzing biological data and conducting simulation calculations, the efficiency of discovering new targets and new drugs can be improved; the R&D cycle can be shortened and R&D costs reduced; promoting the development, application, integration, and sharing of health care big data, and exploring the establishment of a unified clinical big data platform. According to statistics, as of the end of 2023, there are about 80 AI pharmaceutical companies in China, including Tandem AI, Insilico Medicine, XtalPi, and Deep Potential Technology.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.